Document Detail

The role of endothelin-1 in pulmonary arterial hypertension.
MedLine Citation:
PMID:  25405182     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Pulmonary arterial hypertension (PAH) is a rare but debilitating disease, which if left untreated rapidly progresses to right ventricular failure and eventually death. In the quest to understand the pathogenesis of this disease differences in the profile, expression and action of vasoactive substances released by the endothelium have been identified in patients with PAH. Of these, endothelin-1 (ET-1) is of particular interest since it is known to be an extremely powerful vasoconstrictor and also involved in vascular remodelling. Identification of ET-1 as a target for pharmacological intervention has lead to the discovery of a number of compounds that can block the receptors via which ET-1 mediates its effects. This review sets out the evidence in support of a role for ET-1 in the onset and progression of the disease and reviews the data from the various clinical trials of ET-1 receptor antagonists for the treatment of PAH.
Adrian H Chester; Magdi H Yacoub
Publication Detail:
Type:  Journal Article; Review     Date:  2014-06-18
Journal Detail:
Title:  Global cardiology science & practice     Volume:  2014     ISSN:  2305-7823     ISO Abbreviation:  Glob Cardiol Sci Pract     Publication Date:  2014  
Date Detail:
Created Date:  2014-11-18     Completed Date:  2014-11-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101613130     Medline TA:  Glob Cardiol Sci Pract     Country:  Qatar    
Other Details:
Languages:  eng     Pagination:  62-78     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  STREAM and FAST-MI - Pharmacoinvasive therapy: A continued role for fibrinolysis in the primary PCI ...
Next Document:  The discovery of pulmonary circulation: From Imhotep to William Harvey.